Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

This publication has 17 references indexed in Scilit:

• 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
  JACC, 2018
• A comparison of approaches for adjudicating outcomes in clinical trials
  Trials, 2017
• Streamlining cardiovascular clinical trials to improve efficiency and generalisability
  Heart, 2017
• Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium
  American Heart Journal, 2015
• Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
  New England Journal of Medicine, 2014
• Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])
  American Heart Journal, 2010
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
  The Lancet, 2003
• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• Effect of Carvedilol on Survival in Severe Chronic Heart Failure
  New England Journal of Medicine, 2001
• TIME-DEPENDENT COVARIATES IN THE COX PROPORTIONAL-HAZARDS REGRESSION MODEL
  Annual Review of Public Health, 1999